REPORT ID 13347

United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Report 2017

Publish Date
21-Nov-17
Pages
108
Format
Electronic (PDF)

In this report, the United States High Performance Active Pharmaceutical Ingredients (HPAPI) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of High Performance Active Pharmaceutical Ingredients (HPAPI) in these regions, from 2012 to 2022 (forecast).

United States High Performance Active Pharmaceutical Ingredients (HPAPI) market competition by top manufacturers/players, with High Performance Active Pharmaceutical Ingredients (HPAPI) sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bristol-Myers Squibb
    Novartis
    Sanofi Aventis
    Pfizer
    Lonza
    Novasep
    Hospira
    BASF
    Merck
    Bayer
    Teva Pharmaceuticals
    Boehringer Ingelheim

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Synthetic Ingredients
    Biological Ingredients
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Oncology
    Glaucoma
    Anti-diabetic
    Cardiovascular
    Musculoskeletal
    Hormonal
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Report 2017
1 High Performance Active Pharmaceutical Ingredients (HPAPI) Overview
    1.1 Product Overview and Scope of High Performance Active Pharmaceutical Ingredients (HPAPI)
    1.2 Classification of High Performance Active Pharmaceutical Ingredients (HPAPI) by Product Category
        1.2.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Synthetic Ingredients
        1.2.4 Biological Ingredients
        1.2.5 Others
    1.3 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market by Application/End Users
        1.3.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Oncology
        1.3.3 Glaucoma
        1.3.4 Anti-diabetic
        1.3.5 Cardiovascular
        1.3.6 Musculoskeletal
        1.3.7 Hormonal
        1.3.8 Others
    1.4 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market by Region
        1.4.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West High Performance Active Pharmaceutical Ingredients (HPAPI) Status and Prospect (2012-2022)
        1.4.3 Southwest High Performance Active Pharmaceutical Ingredients (HPAPI) Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic High Performance Active Pharmaceutical Ingredients (HPAPI) Status and Prospect (2012-2022)
        1.4.5 New England High Performance Active Pharmaceutical Ingredients (HPAPI) Status and Prospect (2012-2022)
        1.4.6 The South High Performance Active Pharmaceutical Ingredients (HPAPI) Status and Prospect (2012-2022)
        1.4.7 The Midwest High Performance Active Pharmaceutical Ingredients (HPAPI) Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of High Performance Active Pharmaceutical Ingredients (HPAPI) (2012-2022)
        1.5.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2022)
        1.5.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate (2012-2022)

2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Competition by Players/Suppliers
    2.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Average Price by Players/Suppliers (2012-2017)
    2.4 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Competitive Situation and Trends
        2.4.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Concentration Rate
        2.4.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturing Base Distribution, Sales Area, Product Type

3 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Region (2012-2017)
    3.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue and Market Share by Region (2012-2017)
    3.3 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Price by Region (2012-2017)

4 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue and Market Share by Type (2012-2017)
    4.3 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Price by Type (2012-2017)
    4.4 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate by Type (2012-2017)

5 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (Volume) by Application (2012-2017)
    5.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Application (2012-2017)
    5.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States High Performance Active Pharmaceutical Ingredients (HPAPI) Players/Suppliers Profiles and Sales Data
    6.1 Bristol-Myers Squibb
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Novartis
        6.2.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Sanofi Aventis
        6.3.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Pfizer
        6.4.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Lonza
        6.5.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Novasep
        6.6.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Hospira
        6.7.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 BASF
        6.8.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Merck
        6.9.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Bayer
        6.10.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Teva Pharmaceuticals
    6.12 Boehringer Ingelheim

7 High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturing Cost Analysis
    7.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of High Performance Active Pharmaceutical Ingredients (HPAPI)

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of High Performance Active Pharmaceutical Ingredients (HPAPI) Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Volume Forecast by Type (2017-2022)
    11.3 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Volume Forecast by Application (2017-2022)
    11.4 United States High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer